A Missense Mutation in CASK Causes FG Syndrome in an Italian Family  by Piluso, Giulio et al.
ARTICLE
A Missense Mutation in CASK
Causes FG Syndrome in an Italian Family
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Marina Di Domenico,1 Stefania Aurino,3 Charles E. Schwartz,4 Giovanni Neri,5 and Vincenzo Nigro1,3
First described in 1974, FG syndrome (FGS) is an X-linked multiple congenital anomaly/mental retardation (MCA/MR) disorder, char-
acterized by high clinical variability and genetic heterogeneity. Five loci (FGS1-5) have so far been linked to this phenotype on the X
chromosome, but only one gene, MED12, has been identiﬁed to date. Mutations in this gene account for a restricted number of FGS
patients with a more distinctive phenotype, referred to as the Opitz-Kaveggia phenotype. We report here that a p.R28L (c.83G/T)
missense mutation in CASK causes FGS phenotype in an Italian family previously mapped to Xp11.4-p11.3 (FGS4). The identiﬁed
missense mutation cosegregates with the phenotype in this family and is absent in 1000 control X chromosomes of the same ethnic
origin. An extensive analysis of CASK protein functions as well as structural and dynamic studies performed by molecular dynamics
(MD) simulation did not reveal signiﬁcant alterations induced by the p.R28L substitution. However, we observed a partial skipping of
the exon 2 of CASK, presumably a consequence of improper recognition of exonic splicing enhancers (ESEs) induced by the c.83G/T
transversion. CASK is a multidomain scaffold protein highly expressed in the central nervous system (CNS) with speciﬁc localization to
the synapses, where it forms large signaling complexes regulating neurotransmission. We suggest that the observed phenotype is most
likely a consequence of an altered CASK expression proﬁle during embryogenesis, brain development, and differentiation.Introduction
FG syndrome (FGS [MIM 305450]), also known as Opitz-
Kaveggia syndrome,1 is a rare X-linked disorder character-
ized by multiple congenital anomalies and mental retarda-
tion (MCA/MR). Several families have been reported to
date, increasing the phenotype variability.2–8
FGS is characterized by developmental delay, congenital
hypotonia, complete or partial agenesis of the corpus
callosum, characteristic face, relativemacrocephaly, consti-
pation (with or without anal/intestinal anomalies), and an
unusual personality.1,2 However, FGS has a variable clinical
presentation and clinical diagnosis may be difﬁcult, espe-
cially in sporadic patients.9
FGS is genetically heterogeneous and ﬁve loci have so far
been identiﬁed on the X chromosome. The FGS1 (MIM
305450), FGS3 (MIM 300406), and FGS4 (MIM 300422)
loci have been mapped to Xq12-q22.1, Xp22.3, and
Xp11.4-p11.3, respectively, by linkage analysis.6,10–12
The FGS2 (MIM 300321) locus was located at Xq11 or
Xq28 by analyzing an X chromosome inversion [inv(X)
(q11q28)].13,14 Recently, the FGS5 (MIM 300581) locus
has been identiﬁed by detecting an Xq22.3 duplication
in a Brazilian FGS patient by CGH array.15
Even more recently, a recurrent c.2881C/T (p.R961W)
mutation in the MED12 gene (MIM 300188) at Xq13 has
been shown to be responsible for FGS in 6 out of 45 families
with the clinical diagnosis of Opitz-Kaveggia syndrome,
including theonly survivingaffectedmale fromtheoriginal
Opitz-Kaveggia family.16 MED12 represents the ﬁrst FGS162 The American Journal of Human Genetics 84, 162–177, Februargene identiﬁed. Its causal role appears to be restricted to
the Opitz-Kaveggia phenotype, which seems to represent
a speciﬁc phenotype within the broad spectrum of FGS.9
A different p.N1007S (c.3020A/G) missense mutation in
MED12 has also been found in the original family with Lu-
jan-Fryns syndrome (MIM 309520) and in another distinct
family.17 In addition, mutations in UPF3B (MIM 300298),
BRWD3 (MIM 300553), and FLNA (MIM 300017) genes
have also been found in sporadic patients with clinical
features overlapping the FGS phenotype.18–20 Most prob-
ably, FLNA corresponds to the FGS2 gene and the others
should be considered novel putative FGS loci.21
Previously, we clinically and genetically characterized an
Italian FGS family that included 31 members with 3
affected males and 2 obligate carriers.12 The affected males
showed many clinical signs typical of FGS such as mental
retardation, relative macrocephaly, congenital hypotonia,
severe constipation, and behavioral disturbances.
By linkage analysis, we identiﬁed the FGS4 locus local-
ized in Xp11.4-p11.3 between DXS8113 and sWXD805,
corresponding to a 4.4 Mb region on the X chromosome.
Here, we describe CASK (MIM 300172) as the FGS4 gene
mutated in this Italian FGS family. CASK maps to Xp11.4
and encodes a multidomain scaffold protein highly ex-
pressed in the central nervous system (CNS), but also, at
lower levels, in epithelial cells and other tissues.22,23
In our FGS patients, we found a c.83G/T (p.R28L)
CASK mutation that cosegregates with the phenotype.
The mutation changes a highly conserved amino acid
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Table 1. Candidate Genes at FGS4 Locus
Acc. Number Gene Symbol Gene Exons Amplicons Status
NM_001123384 BCOR BCL6 interacting corepressor 15 24 A
NM_005765 ATP6AP2 ATPase, Hþ transporting, lysosomal accessory protein 2 9 9 A
NM_144970 CXorf38 chromosome X open reading frame 38 (hypothetical protein) 7 6 A
NM_004229 MED14 mediator complex subunit 14 31 31 A
NM_001039590 USP9X ubiquitin specific peptidase 9, X-linked 45 44 A
NM_001356 DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 17 17 A
NM_022567 NIX nyctalopin 2 N/A
NM_001126054 CASK calcium/calmodulin-dependent serine protein kinase 27 27 A
NM_001097579 GPR34 G protein-coupled receptor 34 3 4 A
NM_080817 GPR82 G protein-coupled receptor 82 3 5 A
NM_000240 MAOA monoamine oxidase A 15 N/A
Abbreviations: A, analyzed; N/A, not analyzed by CMS.calcium/calmodulin-dependent protein kinase II (CaM-
kinase domain).22
We show that the p.R28L mutation did not interfere
with the known interactions and functions involving
CaM-kinase domain, but it may act by producing a partial
skipping of the exon 2 as a result of improper recognition
of exonic splicing enhancers (ESEs). The resulting aberrant
CASK exon 2-skipped transcript is out of frame. We specu-
late that an altered CASK expression proﬁle during
embryogenesis and CNS development could be at the basis
of the FGS4 phenotype.
Material and Methods
FGS4 Family Members
The clinical description of the patients was previously reported.12
In accordance with Italian law, an informed consent was obtained
from all family members involved in this study.
Gene Selection and Primer Design
The 4.4 Mb region of the FGS4 locus between DXS8113 and
sWXD805 was scanned on UCSCGenome Browser. Eleven known
geneswere identiﬁed. Accessionnumber of the reference sequence,
gene symbol, number of coding exons, and number of amplicons
analyzed inmutation screening are listed in Table 1 (UCSCHuman
Genome Database; freeze March 2006).24,25 All oligonucleotides
utilized in mutation screening and in all other PCR protocols
were designed with web-based tool Primer3.26
Comparative Mutation Scanning
The major problem in identifying causative mutations in large
genomic regions is the huge number of potential candidate muta-
tions to be distinguished from polymorphisms or private variants.
For this study, we set up comparative mutation scanning (CMS)
analysis, a DHPLC-based approach that performs, in a very short
time, a comparison of each candidate mutation with all members
of the family, an initial pool of controls, and (when necessary)
a second larger pool of controls.
CMS analysis requires an accurate deﬁnition of DHPLC condi-
tions. For each gene analyzed, we performed DHPLC optimization
by designing oligonucleotide pairs to amplify each exon and its
intronic ﬂanking regions, carefully evaluating the GC content of
primers and PCR products to facilitate the next temperature opti-The Americmization. We utilized the same annealing temperature for all
the exons, allowing different exons to be ampliﬁed on the same
96/384-well plate.
For this X-linked disease, each exon was ﬁrst ampliﬁed with
genomicDNA froma carrier female, an affectedmale, and a control
male. PCR products were then analyzed by agarose gel electropho-
resis to highlight any possible gene deletion/duplication. DHPLC
conditions were optimized on a Wave 3500HT system with Navi-
gator1.6.4 softwareaccordingtomanufacturer’s indications (Trans-
genomic Inc.). We utilized Rapid DNAmethods with a 2-min-long
gradient and a ﬂow rate of 1.5 ml/min. For CASK, primer pairs,
annealing temperature, length of amplicons, ampliﬁed exons,
column temperature, and percentage of B solution at start gradient
are listed in Table S1 available online. The same data can be re-
quested from the authors for all the other genes at the FGS4 locus.
For each exon analyzed, different pooled DNAs were used in
PCR reaction, differently assembled according to the mechanism
of inheritance. The samples were dispensed into ready-to-use
96-well plates in which each row contained 12 mixes of pooled
DNAs, as shown in Table S2.
PCR products were run on DHPLC under the optimized condi-
tions. By using the CMS approach, we were able to distinguish
rapidly between mutation and polymorphism. According to the
mechanism of inheritance, heteroduplexes present in samples
2–5 and absent in samples 1 and 6–12 were indicative of a muta-
tion (see Table S2). For the more frequent polymorphisms, the
number of control chromosomes analyzed was sufﬁcient to
exclude these from further analysis, reducing time and cost of
the mutation screening.
Each variation observed in patients and absent in controls was
further characterized by direct sequencing, and its pathogenetic
role was validated by analyzing at least 1000 control X chromo-
somes of the same ethnic origin.
FGS/XLMR Patient Recruitment
One hundred and one affected individuals (91 males and
10 females) with FGS/XLMR phenotype were collected worldwide
with the support of several medical genetics centers. They were
classiﬁed into three different groups: (1) 32 familial cases with
linkage data overlapping the FGS4 locus (27 XLMR patients and
5 FGS patients); (2) 27 familial cases without linkage data; and
(3) 42 sporadic FGS patients.
We received DNA and/or blood samples. For blood samples,
DNA was extracted via a standard protocol.27 For the members
of the FGS family under study and other Italian FGS patients,an Journal of Human Genetics 84, 162–177, February 13, 2009 163
EBV-transformed lymphocyte cell lines were also established via
standard procedures.28 An informed consent was obtained from
all the human subjects involved in this study.
Construction of Fusion Genes and Expression
Plasmids
The sequences encoding the CaM-kinase domain of CASK
(CASKwt: nt. 12–1003 of NM_003688; aa. 5–334) as well as the in-
teracting domains of Mint-1 (MNT1: nt. 345–1336 of NM_001163;
aa. 116–445), Caskin 1 (CSK1: nt. 1029–1496 of NM_020764; aa.
344–498), and Carom (CARM: nt. 1833–2223 of NM_014824; aa.
612–740) were ampliﬁed by RT-PCR from total human brain
RNA (OriGene Technologies) with a thermostable DNA poly-
merase with proofreading activity (PfuTurbo DNA polymerase;
Stratagene) and cloned in pBlueScriptSK vector. After automated
full-length sequencing to conﬁrm that no base errors occurred,
each coding fragment was in-frame subcloned in pGBKT7 and
pGADT7 yeast two-hybrid system vectors, in pGEX-2TK vector
for bacterial expression of GST-fusion proteins, and in a modiﬁed
pSG5 vector for expression in eukaryotic cells of proteins
N-terminal labeled with the c-Myc epitope tag.
The p.R28L mutation under study (CASKmut) and the hypo-
morphic double mutant (p.S24D and p.V26L) (CASKsv)29 were
obtained by site-speciﬁc direct mutagenesis of the wild-type
coding sequence of the CaM-kinase domain of CASK cloned in
the required vectors (QuikChange Site-Directed Mutagenesis Kit;
Stratagene).
Yeast Two-Hybrid Assay and Library Screening
The pGBKT7-CASKwt and pGBKT7-CASKmut plasmids were sepa-
rately transformed in S. cerevisiae AH109 strain by lithium acetate
method, selected on Trp plates, and used as baits. Conversely,
pGADT7-MNT1, pGADT7-CSK1, and pGADT7-CARM plasmids
were separately transformed in S. cerevisiae Y187 strain with the
samemethod, selectedonLeuplates, andused as preys. According
to manufacturer’s indications (Clontech), the pTD1 and p53
control vectors as well as the pGBKT7 and pGADT7 empty vectors
were also separately transformed in the speciﬁc yeast strain and
utilized as positive and negative controls of interaction, respec-
tively. Each bait was mated with prey lines and diploid cells were
selected on Trp and Leu plates. The protein-protein binding
was then detected by selecting positive clones on minimal Trp,
Leu, His, and Ade plates, as a result of the activation of HIS3
and ADE2 reporter genes. As a further control of all tested interac-
tions, plasmid vectors and yeast strains were also opportunely
switched.
The screening of a human brain cDNA library cloned in pACT2
vector and pretransformed in S. cerevisiae Y187 strain was carried
out according tomanufacturer’s speciﬁcations (Clontech). In brief,
pGBKT7-CASKwt and pGBKT7-CASKmut plasmids separately
transformed in S. cerevisiae AH109 strain were grown overnight
in SD/Trp liquid medium. After centrifugation, pellets of both
bait strains were separately resuspended in 5 ml of the same liquid
medium. For mating, each bait strain was combined with an
aliquot of the pretransformed cDNA library in 50 ml of YPDA
liquidmedium and incubated at 30C for 24 hr with slow shaking.
The diploid strains were plated on high-stringency Trp, Leu,
His, and Ade synthetic medium. Hisþ and Adeþ diploid colonies
were patched on selective plates and assayed for b-galactosidase
activity by colony-lift ﬁlter assay. Total DNA was extracted from
Hisþ, Adeþ, and LacZþ colonies, and pACT2 library plasmids164 The American Journal of Human Genetics 84, 162–177, Februarwere then rescued after transformation in XL1-blue competent
cells (Stratagene). The pACT2 library plasmids trapped by using
pGBKT7-CASKwt or pGBKT7-CASKmut plasmids as baits were
tested for speciﬁcity by cotransformation into AH109 strain either
alone, in combination with the pGBKT7-CASKwt or pGBKT7-
CASKmut constructs, or in combination with negative and posi-
tive control plasmids. The cDNA inserts from veriﬁed CaM-kinase
domain-interacting clones were characterized by direct se-
quencing.
In Vitro GST Pull-Down Assay
The in vitro GST pull-down assay was performed as previously
described.30 In brief, the wild-type ormutant CaM-kinase domains
of CASK were expressed in BL21 E. coli cells (Stratagene) as GST-
fusion protein (pGEX-CASKwt and pGEX-CASKmut plasmids)
and puriﬁed on glutathione-agarose beads. Conversely, the inter-
acting domains of Mint-1 and Caskin 1 cloned in a modiﬁed
pSG5 vector with c-Myc epitope tag to the N terminus (pSG5Myc-
MNT1 and pSG5Myc-CSK1 plasmid) were transiently expressed
in COS-7 eukaryotic cells. COS-7 cell protein extracts were then
incubated with GST-CASKwt, GST-CASKmut, and GST-alone
bead-bound fusion proteins. After extensive washing, samples
were run on 10% SDS-polyacrylamide gel and analyzed by western
blotting with an anti-Myc monoclonal antibody (Hybridoma
9E10).
In Vitro Phosphorylation Assay
Phosphorylation assay was performed as previously described.29
All the experiments were carried out in 50 mMTris-HCl (pH 7.2)
and 50 mM KCl buffer containing 2 mM EDTA or 4 mM MgCl2.
In brief, bead-bound GST-fusion proteins corresponding to the
wild-type, the mutant (p.R28L), and the double hypomorphic
mutant (p.S24D and p.V26L) CaM-kinase domain of CASK were
incubated in equimolar quantity with 1 mM [g-32P]ATP (speciﬁc
activity: 23 107 cpm) (PerkinElmer) for 1 hr at 30Cwith shaking.
The reactionwas stopped by adding an equal volumeof 23 loading
buffer (250 mM Tris-HCl [pH 6.8], 8 M urea, 8% SDS, 200 mM
dithiothreitol, and 0.005% bromphenol blue), and after boiling,
samples were separated by SDS-PAGE, Coomassie blue stained,
and visualized on a phosphorimager (Typhoon; GE Healthcare).
The incorporated radioactivity was measured with ImageQuant
software (GEHealthcare) and, after background subtraction, values
were normalized by comparison with protein quantities.
Molecular Dynamics Simulation
All MD simulations were performed with GROMACS (GROningen
Machine for Chemical Simulations) v.3.2 and united-atom force-
ﬁeld.31 The starting conﬁguration of the CaM-kinase domain of
CASK was obtained by crystallographic coordinates (PDB: 3c0h)
with routines included in Visual Molecular Dynamics (VMD)
package,32 also used to introduce the p.R28L substitution. For all
MD simulations, the protein was placed in the center of a cubic
box of approximate dimensions (8.48 3 8.48 3 8.48 nm3). The
minimum distance between the protein and the edge of the box
was 1.0 nm. All water molecules with their oxygen closer than
0.23 nm to anynonhydrogen protein atomor crystal water oxygen
were removed. The box was full of equilibrated SPC (Single Point
Charge) rigid water molecules. Initial velocities were taken from
a Maxwellian distribution at 300 K. Simulations were performed
keeping temperature and pressure coupled to external reference,
with a Berendsen thermostat and barostat;33 coupling constantsy 13, 2009
were 0.1 and 1.0 ps, respectively. All molecular groups (protein,
water, and counterions) were coupled independently. Long-range
electrostatic interactions were calculated with the Particle Mesh
Ewald (PME) method with a 9 A˚ cut-off.34 The LINear Constraint
Solver (LINCS) algorithm was used to restrain bond lengths.35 In
order to relieve unfavorable nonbonded interactions with the
added water molecules, each system was energy minimized by
a steepest descent algorithm followed by a short 100 ps simulation
during which the protein and nonhydrogen atoms were harmoni-
cally restrained with a force constant of 1000 kJ/mol$nm2. All
restraints were then removed and each simulation was run for
2.5 ns saving coordinates and velocities every 5 ps for subsequent
analysis. Typical CPU times on HP 6200 Workstation running
Linux Kernel 2.6.3-7 were 1 day per ns. The simulated system
comprised 3,083 protein atoms and 14,000 water molecules. Each
simulation was stopped after 2.5 ns. As previously discussed, the
ﬁrst nanosecond of each simulation is treated as an equilibration
period and is not considered in the analysis. To assess the stability
of the simulations, the rmsd of protein atoms with respect to the
X-ray structure, the solvent-accessible surface area, and the
presence of secondary structure elements were monitored.
RT-PCR and Real-Time RT-PCR
Total RNA was extracted with TRIzol reagent (Invitrogen) from
EBV-transformed lymphocyte cell lines from affected males,
carrier females, and normal individuals from the FGS family as
well as additional healthy male and female controls. RNAs were
then retrotranscripted with SuperScript III RT (Invitrogen) and
random primers, according to manufacturer’s speciﬁcations.
Single-strand cDNAs were used in later experiments.
To test any putative effect of the c.83G/T (p.R28L)mutation on
splicing of CASK exon 2, different primer pairs were designed and
utilized in RT-PCR and real-time RT-PCR experiments (Table S3).
An exon 1-speciﬁc primer (CASK16/F) was combined with an
exon 3-speciﬁc primer (CASK268/R) to amplify a 253-bp-long frag-
ment from the normal CASK transcript or a 140-bp-long fragment
expected whenCASK exon 2 is skipped. The exon 1-speciﬁc primer
(CASK16/F) was also combined with a downstream primer in exon
8 (CASK744/R). The expected PCR products were 729 bp and 616
bp long, respectively.
RT-PCR was performed in a ﬁnal volume of 20 ml containing 2 ml
of cDNA, 13 PCR Buffer II (Applied Biosystems), 1 mM MgCl2,
1 mM dNTPs, 0.5 mM of each primer, and 0.5 U of AmpliTaq
Gold DNA polymerase (Applied Biosystems). The cycling condi-
tions consisted of a ﬁrst step at 96C for 7 min and 30 cycles of
30 s at 96C, 1 min at 63C, and 3 min plus 3 s/cycle at 68C.
To quantify the expression level of the exon 2-skipped CASK
transcript, further primers were designed to be speciﬁcally used
in quantitative real-time RT-PCR experiments (Table S3).
To discriminate unskipped and exon 2-skipped isoforms of
CASK transcripts, two additional primers were designed, the ﬁrst
overlapping exon 1-exon 2 (CASKsp1-2/F) junction and the
second overlapping exon 1-exon 3 (CASKsp1-3/F). The normal
CASK transcript was detected with CASKsp1-2/F and CASK268/R
primer pair (ampliﬁed product 220 bp long), whereas the exon
2-skipped isoform of CASK transcript was detected by combining
CASKsp1-3/F primer with a downstream primer in exon 5
(CASK398/R; ampliﬁed product 240 bp long). Total CASK tran-
scripts were detected by using CASK2310/F and CASK2545/R
primer pair (ampliﬁed product 236 bp long), designed in exons
25 and 26, respectively. GAPDH was ampliﬁed as housekeeping
gene for data normalization.The AmericReal-time RT-PCR experiments were performed on ABI Prism
7900HT System (Applied Biosystems) with SYBRGreen PCRMaster
Mix (Applied Biosystems) according to manufacturer’s instruc-
tions. In order to prevent PCR carry-over contamination, Uracil
N-glycosylase was used (Amperase UNG, Applied Biosystems).
Each assay was performed in triplicate and results were normalized
and analyzed with SDS2.1 software (Applied Biosystems).
DNA Sequencing
PCR products and cloned fragments were double-strand
sequenced with BigDye Terminator sequencing chemistry
(Applied Biosystems) and analyzed on an ABI 3130xL automatic
DNA sequencer (Applied Biosystems).
Results
Mutation Screening
To select a candidate gene in the critical region of the FGS4
locus covering a 4.4 Mb region at Xp11.4-p11.3 between
the markers DXS8113 and sWXD805,12 all known genes
in this interval were systematically scanned for mutations
with a new and speciﬁcally deﬁnedDHPLC-based approach
that we named comparative mutation scanning (CMS) (for
a complete description see Material and Methods). The
FGS4 locus region contains at least 11 known genes (UCSC
Human Genome Server, freeze March 2006) (Table 1).
CMS allows the rapid comparison of each sequence vari-
ation within all family members under study and a pool of
normal controls, providing clear indications as to the vari-
ation type and distinguishing a unique variation from
common polymorphisms without the necessity of exten-
sive and very expensive direct sequencing of each variation
observed.
Two genes (NIX andMAOA) were preliminarily excluded
from the screening because the former is involved in
complete congenital stationary night blindness (CSNB1
[MIM 310500]) and is expressed only in retina and
kidney,36 and the latter (MAOA [MIM 309850]) is on the
centromeric boundary of the disease interval, split by the
marker sWXD805. Interestingly, MED14 gene maps at
FGS4 locus37 andMED12, a member of Mediator complex,
was previously reported to be mutated in Opitz-Kaveggia
and Lujan-Fryns syndromes.16,17 AlthoughMED14 escapes
X-inactivation,37 it might represent a good candidate gene.
A total of 167 amplicons were analyzed by CMS. Poly-
morphic variants were identiﬁed in some of the screened
genes, but these SNPs were not useful in narrowing the
linkage interval.
We identiﬁed the p.R28L (c.83G/T) missense mutation
in exon 2 of CASK (Figure 1). CASK encodes a 104 KDa
calcium/calmodulin-dependent serine protein kinase,
preferentially expressed in neuronal cells and involved in
signal transduction at the synapses.
To verify that c.83G/T (p.R28L) mutation was present
only in the three affected males and two carrier females,
CASK exon 2 PCR products ampliﬁed in DNA samples
from 22 family members were digested with Hpy99I. Thean Journal of Human Genetics 84, 162–177, February 13, 2009 165
Figure 1. DHPLC Analysis and Characterization of the c.83G/T Mutation Identified in CASK
In the chromatogram on the left, the elution profile of a normal control (black curve) is compared with the mutant profile (gray curve). On
the right, electropherograms from a normal control male, a carrier female (II.8), and an affected male (III.26) from pedigree12 are shown.
The nucleotide change is boxed.variation fully cosegregated with the phenotype (Figure 2).
In addition, it was absent in 1000 control X chromosomes
of the same ethnic origin.
By aligning the CaM-kinase domain from different hor-
tologs of CASK, we observed that the c.83G/T transver-
sion changes a basic and positively charged, highly
conserved arginine residue at 28 position to a hydrophobic
leucine residue (Figure 3).
Taken together, this experimental evidence strongly sug-
gested that the indentiﬁed missense mutation in CASK
causes FGS in this family.
Patient Recruitment and Analysis
To test the involvement of CASK in FGS or XLMR pheno-
types, a large cohort of FGS/XLMR patients was recruited
worldwide. One hundred and one familial and sporadic
FGS/XLMR patients were collected and analyzed for muta-
tion in CASK by direct sequencing of all the 27 exons
covering the coding sequence and of the upstream
promoter region. No mutations were identiﬁed. This indi-
cates that mutations in CASK represent a rare, if not
a private, cause of FGS.
Functional Analysis of CASK Protein
Together with Velis and Mint-1 or Caskin 1, CASK forms
two alternative tripartite protein complexes on the inner
surface of the presynaptic membrane of the neurons.38–41
The N-terminal CaM-kinase domain of CASK participates
in an evolutionarily conserved complex with Mint-1,166 The American Journal of Human Genetics 84, 162–177, Februaralso present in C. elegans, and in a mammalian-speciﬁc
complex with Caskin 1.
By in vivo and in vitro protein-protein binding assays,
we ﬁrst evaluated whether the p.R28L substitution in
CaM-kinase domain of CASK may interfere with the
described interactions. To detect protein-protein binding
in vivo, we used the yeast two-hybrid system. The CaM-
kinase domain of CASK (residues 5–334) and the interact-
ing domains of Mint-1 (residues 116–445) and Caskin 1
(residues 344–498) were expressed as fusion proteins with
the DNA-binding domain and the transcription activation
domain of GAL4, respectively. The p.R28L substitution was
introduced by direct mutagenesis.
Protein-protein binding was then detected by selecting
positive clones on minimal Trp, Leu, His, and Ade
plates, as a result of the activation of the HIS3 and ADE2
reporter genes. The CaM-kinase domain of CASK interacts
with the speciﬁc domains of Mint-1 and Caskin 1 in yeast,
but these bindings were not modiﬁed by the p.R28L muta-
tion identiﬁed in our patients (Figure 4A). The same result
was also obtained by performing in vitro GST pull-down
assays (Figure 4B).
The multidomain protein Carom was also reported to
bind the CaM-kinase domain of CASK in epithelial cell
junctions.42 This protein is also expressed in brain. The
interaction with the CaM-kinase domain of CASK was
not shown to be modiﬁed by p.R28L mutation in an
in vivo protein-protein binding assay (data not shown).
To verify whether as-yet-uncharacterized CASK interac-
tions may be affected by the p.R28L missense mutationy 13, 2009
Figure 2. The c.83G/T Mutation Fully Cosegregates with the Phenotype in Our FGS Family
CASK exon 2 and intronic flanking regions were amplified by PCR in DNA samples from all the individuals in the pedigree and digested by
Hpy99I. This restriction site is lost when the c.83G/T substitution is present. Agarose gel electrophoresis of Hpy99I-digested PCR prod-
ucts clearly indicates that the c.83G/T mutation is present only in the affected males (hemizygotes; 217-bp-long band) and carrier
females (heterozygotes; 79-, 138-, and 217-bp-long bands) and is absent in all the other individuals from pedigree (79- and 138-bp-
long bands).in the CaM-kinase domain, we also utilized the yeast two-
hybrid system to screen a human brain cDNA library using
as bait only the CaM-kinase domain of CASK (wild-type
and mutant). Although novel putative interactors for the
CaM-kinase domain of CASK were identiﬁed (unpublished
data), these interactions were not speciﬁcally modiﬁed
when using the mutant CaM-kinase domain of CASK as
bait. Altogether, these results suggest that the observedThe Americphenotype is not determined by the alteration of the gross
binding property of CaM-kinase domain as a consequence
of the p.R28L substitution in CASK protein.
Phosphorylation regulates CASK activity. The Cdk5-
dependent phosphorylation of CASK dynamically controls
its localization to the synapses and the interaction
between CASK and liprin-a in developing synapses,
promoting synaptogenesis and neurotransmitter vesicleFigure 3. Alignment of CaM-Kinase Domain from Different Hortologs of CASK
The protein sequences of CASK from H. sapiens (NP_003679), M. musculus (NP_033936), R. norvegicus (NP_071520), D. melanogaster
(NP_524441), X. tropicalis (NP_001016204), D. rerio (NP_694420), and C. elegans (NP_001024587) were aligned with Clustal W soft-
ware.70 Amino acid conservation was highlighted with GeneDoc software. Only the N terminus region is shown and CaM-kinase domain
of CASK is enclosed in square brackets. An arrow indicates the position of p.R28L substitution.an Journal of Human Genetics 84, 162–177, February 13, 2009 167
trafﬁcking.43,44 More recently, crystallographic studies
revealed that the CaM-kinase domain of CASK is a constitu-
tively active kinase domain, able to phosphorylate itself
and at least the neurexin-1 CASK-protein partner.29
Interestingly, the p.R28L substitution identiﬁed in FGS
patients is located very close to the nucleotide-binding
pocket of the CaM-kinase domain. By in vitro autophos-
phorylation assay, we tested whether the p.R28L mutation
could interfere with ATP binding. We compared the auto-
phosphorylation of the CaM-kinase domain (wild-type
Figure 4. In Vivo and In Vitro Binding Assays of CaM-Kinase
Domain of CASK with the Interacting Domains of Mint-1 and
Caskin 1
(A) By yeast two-hybrid system, the CaM-kinase domain of CASK in-
teracted with these partners and the p.R28L substitution did not
modify binding properties. In the grid, strong and weak growth
is indicated with black and gray disks, respectively. A mild autoac-
tivation of reporter genes was observed for Mint-1. The p53
plasmid encoding murine p53 fused to GAL4 DNA-binding domain
and the pTD1 plasmid encoding SV40 large T-antigen fused to
GAL4 activating domain were used as positive control. pGBKT7
and pGADT7 empty plasmids were used as negative control.
(B) For GST pull-down assays, the interacting domains of Caskin 1
and Mint-1, N-terminal labeled with c-Myc epitope tag, were tran-
siently expressed in COS-7 cells. Protein extracts from Caskin
1-transfected cells (lanes 1–4), Mint-1-transfected cells (lanes
5–8), and untransfected cells (lanes 9–12) were incubated with
GST bead-bound fusion proteins: GST-CASKwt, GST-CASKmut, and
GST alone. Western blotting analysis with an anti-Myc monoclonal
antibody did not reveal differences in binding properties of
CaM-kinase domain of CASK as a result of p.R28L substitution.168 The American Journal of Human Genetics 84, 162–177, Februarand mutant), puriﬁed as GST-fusion proteins, with the
hypomorphic mutant of CaM-kinase domain reported
by Mukherjee et al.29 in which the serine at position 24
and the valine at position 26, both involved in ATP
binding, were mutated to aspartic acid and leucine, respec-
tively. The p.R28L mutation only weakly reduced the auto-
phosphorylation levels of CASK CaM-kinase domain,
which did not have statistical signiﬁcance (Figure 5).
Molecular Dynamics Simulations
In order to investigate potential modiﬁcations in the
protein structure and dynamics induced by p.R28L substi-
tution,we performedmolecular dynamics (MD) simulation
bothonwild-type andmutantCaM-kinasedomainofCASK
starting from crystallographic coordinates (PDB: 3c0h).29
Trajectories of 2.5 nswere sufﬁcient to obtain stable confor-
mations for both wild-type and mutant structures (see
Material and Methods and Figure 6A). By comparing the
structural features of the two MD-simulated proteins, they
appeared as a/b structures highly similar in the secondary
structure as well as in the spatial organization (Figure 6B).
Small differences in the secondary structure were localized
only in the segment 51-54 (yellow colored in Figure 6B).
These four residues were coiled in the wild-type while
they were in a turn in the p.R28L mutant protein. In the
CASK CaM-kinase domain structures containing AMPPNP,
the50AMPportionof theAMPPNP ligand showedanalmost
superimposable conformation for wild-type and mutant
(Figure 6C). The environment of the ligand-binding site
appears only slightly different by comparing wild-type
versus mutant CaM-kinase domain of CASK (Figure 6D)
and the hydrogen bonding network is substantially similar
(Figure 6D and Table S4) to that previously reported.29 Only
fewhydrogenbonds are lacking in thep.R28LmutantCaM-
kinase domain of CASK. Consequently, persistence time of
the ligand in the correct geometry to perform its catalytic
action could be slightly decreased. This observation may
justify the small reduction experimentally observed in the
autophosphorylation assay.
To exclude that the p.R28L substitution in the CaM-
kinase domain of CASK could cause some structural
hindrance to ligand access, we also performed MD simula-
tions in the absence of the ligand. The spatial organization
of thewild-type andmutant proteinswere very similar (e.g.,
the activation segment29), excluding the presence of
marked structural and/or energetic barriers in the mutant
CASK protein (data not shown).
Functional Analysis of CASK Transcript
Point mutations in the coding regions of genes are
commonly assumed to exert their effects by altering single
amino acids in the encoded proteins. However, nonsense,
missense, and even translationally silent mutations can
inactivate genes by inducing the splicing machinery to
skip the mutant exons.45
To evaluate whether the c.83G/T (p.R28L) missense
mutation found in exon 2 of CASK may modify they 13, 2009
consensus sequence of exonic splicing enhancers (ESEs)
interfering with the correct splicing of the exon, the wild-
type and mutant sequence of CASK exon 2 were scanned
with ESEﬁnder, a software tool used to identify putative
ESEs responsive to the human SR proteins SF2/ASF, SC35,
SRp40, andSRp55.46A cluster ofﬁveoverlappingESEmotifs
was clearly identiﬁed in the 50 half of the wild-type
sequence of CASK exon 2, including two SF2/ASF motifs,
two SRp55 motifs, and one SRp40 motif. With the mutant
sequence, the same cluster lost one SF2/ASF motif and
acquired a third SRp55 motif, overlapping the others and
presenting a higher score (Figure 7).
To verify in a natural context whether the identiﬁed
missense mutation may affect an ESE function by altering
the splicing of exon 2 of CASK, we used EBV-transformed
lymphocyte cell lines from affected, carrier, and normal
individuals from the FGS family to test by RT-PCR any
putative effect on the splicing in vivo.
CASK is normally expressed in lymphocytes. With
a speciﬁc primer pair (CASK16/F and CASK268/R) covering
a 253-bp-long cDNA region that includes exons 1–3 (Table
S3 and Figure 8A), a 140-bp-long exon 2-skipped transcript
was detected, at a low level, in the proband (III.26), in the
two affected maternal uncles (II.11 and II.17, data not
shown), and in the carrier grandmother (I.2), but was
undetectable in the carrier mother (II.8) as well as in
normal individuals from pedigree and controls (Figure 8A).
Figure 5. In Vitro Autophosphorylation
Assay of CASK CaM-Kinase Domain
All the experiments were carried out as
described.29 Equimolar quantities of puri-
fied GST bead-bound fusion proteins (GST
alone, GST-CASKwt, GST-CASKmut, and GST-
CASKsv) were incubated with [g-32P]ATP
(specific activity: 2 3 107 cpm) in Tris-
KCl buffer under two different conditions:
2 mM EDTA or 4 mM Mg2þ. The panel
(from bottom) depicts Coomassie blue stain
of SDS gel and related autoradiogram.
Normalized values of incorporated radioac-
tivity were reported in the upper bar graph
where error bars indicate 5SD. When
compared with the wild-type (CASKwt)
and hypomorphic mutant (CASKsv) of
CASK CaM-kinase domain, p.R28L mutation
(CASKmut) did not seem to generate signif-
icant variations in autophosphorylation of
CaM-kinase domain.
To exclude the possibility that the
exon 2-skipped PCR product could
be the expression of incomplete and
nonfunctional splicing products, we
combined the primer in exon 1
(CASK16/F) with a downstream
primer in exon 8 (CASK744/R) to
amplify a 729-bp-long cDNA CASK
fragment (Table S3 and Figure 8B). A speciﬁc 616-bp-long
exon 2-skipped PCR product was likewise observed, at
low level, in the same samples (Figure 8B).
Because no skewed X-inactivation was previously
observed for carrier females of pedigree [I.2 (53:47) and
II.8 (55:45)],12 we investigated whether both alleles
contributed to the CASK transcription in carrier females.
The genomic region of CASK exon 2 and the 253-bp-long
cDNA fragment covering exons 1–3 of CASK transcript
were ampliﬁed in the same sample panel and digested
with Hpy99I (Figure 8C). Interestingly, we observed that
the mother of proband (II.8) preferentially utilized the
wild-type allele for CASK transcription, justifying the fact
that CASK exon 2-skipped transcript was previously unde-
tectable.
To better quantify the exon 2-skipped CASK transcript
and the expression level of CASK, two additional primers
were designed. The ﬁrst overlapped exon 1-exon 2 junction
(CASKsp1-2/F) and was able to amplify exclusively the
normal CASK transcript when combined with a down-
stream primer in exon 3 (CASK268/R). The second overlap-
ped exon 1-exon 3 junction (CASKsp1-3/F) and was able to
amplify speciﬁcally the exon 2-skipped CASK transcript
when combined with a downstream primer in exon 5
(CASK398/R). A thirdprimerpair covering a regionbetween
exons 25-26 (CASK2310/F and CASK2545/R) was used to
detect the total quantity of CASK transcripts (Table S3).The American Journal of Human Genetics 84, 162–177, February 13, 2009 169
Figure 6. Molecular Dynamics Simulation
(A) Structural drift of wild-type (black line) and p.R28L mutant
CaM-kinase domain of CASK (gray line) is shown as root mean
square deviation of all atoms starting from crystallographic coordi-
nates after energy minimization.
(B) Comparison between 3D structures of the wild-type (left) and
p.R28L mutant (right) CaM-kinase domain of CASK obtained from
the 2.5 ns MD simulations at 300 K. The residue at position 28,
in which the mutation occurs, was colored in green, the AMPPNP
ligand was colored in white, and the serine residues at position
147 and 151, targets of autophosphorylation activity,29 were170 The American Journal of Human Genetics 84, 162–177, FebruarBy real-time RT-PCR, we conﬁrmed that the exon 2-skip-
ped transcript was differently expressed in affected males
and carrier females but was not detectable in either unaf-
fected individuals from the pedigree or in controls (Fig-
ure 9A). In fact, the CT value for the CASK exon 2-skipped
speciﬁc PCRproductwas always>30 for normal individuals
frompedigree and controls but was signiﬁcantly reduced in
affected males and carrier females (Figure 9B). After data
normalization, the CASK exon 2-skipped transcripts were
estimated to be approximately 3%–6% of the unskipped
CASK transcript (Figure 9C). The exon 2-skipped transcript
is out-of-frame with a possible effect on CASK protein
levels. Alternatively, by using the ﬁrst methionine down-
stream of the skipped exon 2, a truncated protein without
the ﬁrst 67 amino acids could be produced. This methio-
nine does not conform to Kozak consensus, and neither
qualitative nor quantitative differences were observed by
western blotting analysis on protein extracts from lympho-
cyte cell lines from affected, carrier, and normal individuals
(data not shown). However, we cannot exclude that this
aberrant CASK transcript may be increased in different
cell types or brain regions during embryogenesis, brain
development, and differentiation. Interestingly, Sfrs1 and
Sfrs6 genes encoding SF2/ASF and SRp55, respectively,
show a different expression pathway in adult mouse brain
with a similar low expression of Sfrs1 gene in different brain
regions compared with the very high expression of Sfrs6
gene in cerebral cortex, hippocampal regions, olfactory
bulb, and striatum-like amigdalar nuclei (Allen Institute
for Brain Science, Mouse Brain Atlas). Temporally and
spatially differentiated expression proﬁles have also been
annotated for both genes in mouse embryo at different
stages of CNS development (Eurexpress II; MouseBrain
Gene Expression Map [BGEM]).
Discussion
Since the ﬁrst description in 1974,1 an increasing number
of familial and sporadic cases of FG syndrome have been
diagnosed worldwide, expanding the phenotype spectrum
of this X-linked MCA/MR disorder.
Recently, missense mutations in the MED12 gene at
Xq13 were shown to be responsible for FG/Opitz-Kaveggia
syndrome and Lujan-Fryns syndrome,16,17 most likely rep-
resenting allelic X-linked disorders. Three other genes,
UPF3B, BRWD3, and FLNA, have also been found to be
mutated in patients with FG phenotype.18–21 However,
colored in red. The residues 51–54 that showed small differences
in secondary structure were highlighted in yellow.
(C) The conformation adopted by the 50AMP portion of the AMPPNP
ligand is shown for wild-type (left) and p.R28L mutant (right).
(D) A detailed view of the nucleotide-binding pocket of CASK CaM-
kinase domain in complex with AMPPNP is shown. The color scheme
used in (B) is conserved. In addition, side chains of residues
involved in AMPPNP binding and H bonds (yellow dots) are shown.y 13, 2009
despite recent progress, the molecular defect in a large part
of FGS patients remains elusive.
Here, we identify CASK as a novel FGS gene mutated in
a previously reported Italian FGS family linked to
Xp11.4-p11.3.12
CASK is a member of the membrane-associated guany-
late kinase (MAGUK) family. MAGUKs are characterized
by at least three canonical domains that from the N
terminus include PDZ, SH3, and guanylate kinase (GK)
domains. CASK is the only MAGUK that contains an addi-
tional large N-terminal domain with homology to
calcium/calmodulin-dependent protein kinase II (CaM-
kinase domain).22,47 In brain, CASK localizes to synapses
Figure 7. Analysis of the 113-bp-Long
Coding Sequence of CASK Exon 2 via
ESEfinder Software
As suggested by the authors,46 default
threshold values were used. The bar graphs
and tables below depict the ESE motifs for
different SR proteins (SF2/ASF, SC35,
SRp40, and SRp55) found in wild-type (A)
and c.83G/T mutant (B) CASK exon 2
sequence. In the tables, both positions
(*) from 50 end (through 1) and 30 end
(through 1) are given. The arrows indi-
cate the position of nucleotide substitu-
tion and ESE motif lost or acquired as
a result of the change.
where it interacts with a large array
of protein partners with which it
forms large signaling complexes regu-
lating trafﬁcking, targeting, and
signaling of ion channels in neuro-
transmission.47–49 In addition, CASK
can also translocate to the nucleus
where it interacts with the transcrip-
tion factor TBR1 regulating the
expression of genes involved in
cortical development such as
RELN.50–52
Different animal models clearly
suggest that CASK plays an important
role in embryogenesis, brain develop-
ment, and differentiation, represent-
ing a candidate gene for syndromic
as well as nonsyndromic X-linked
mental retardation.53–57
In C. elegans, the CASK hortologous
Lin-2 is essential for vulva develop-
ment,54 whereas in D. melanogaster,
Caki null mutants show behavioral
and neurotransmitter-release abnor-
malities.56,57 In mammals, Cask
knockoutmice die on day 1 after birth
and do not show major develop-
mental abnormalities apart from a partially penetrant cleft
palate syndrome, suggesting that Cask is required for
mouse survival.53
We characterized a p.R28L (c.83G/T) missense muta-
tion in exon 2 ofCASK segregatingwith the FGS phenotype
in the family under study (Figures 1 and 2), which alters
a highly conserved amino acid in the CaM-kinase domain
unique to CASK (Figure 3). Usually, an altered protein func-
tion should be expected as a result of a missense mutation.
An extensive analysis of the CASK protein was carried out,
but no apparent interaction effects caused by the p.R28L
substitution were demonstrated (Figure 4). In addition, no
marked structural effects caused by the p.R28L substitutionThe American Journal of Human Genetics 84, 162–177, February 13, 2009 171
were observed after an extensive analysis of the trajectories
obtained byMD simulations performed on the CASK CaM-
kinase domain (wild-type and mutant) (Figure 6). We
cannot exclude that this allele is selective in its effects and
cannot bind to as-yet-unknown CASK partners. Neither
can we exclude modiﬁcations in other properties.
Figure 8. RT-PCR Analysis of CASK Transcripts
(A) The CASK cDNA fragment covering exons 1–3 was amplified by RT-PCR. The expected 253-bp-long PCR product was observed in all
samples analyzed by agarose gel electrophoresis (right). cDNA samples are indicated with respect to their position on pedigree (Figure 2).
CM and CF indicate control male or female, respectively. A 140-bp-long PCR product, corresponding to the CASK exon 2-skipped form, was
observed, at low levels, only in the carrier female I.2 and the affected male III.26. The same result was also obtained with the other
affected males (II.11 and II.17) from pedigree (data not shown). The band was undetectable in the other carrier female (II.8), mother
of III.26. The skipping of CASK exon 2 was confirmed by direct sequencing of 140-bp-long PCR fragment (left).
(B) Different primer pairs were used to confirm the CASK exon-2 skipped transcript in the same sample panel. The 616-bp-long PCR product
corresponding to the CASK exon-2 skipped transcript form was observed only in the carrier female I.2 and the affected male III.26.
(C) Hpy99I digestion of CASK exon 2 and its intronic flanking regions, as previously depicted in Figure 2, is combined with the Hpy99I
digestion of CASK cDNA fragment covering exons 1–3. For the same sample panel, agarose gel electrophoresis of Hpy99I-digested genomic
(A) and cDNA (B) PCR products are shown. For carrier females (I.2 and II.8), heterozygosity is confirmed (lanes A), but cDNA PCR products
(lanes B) present a different digestion pattern in which 253- and 185-bp-long fragments show inverted intensity of the bands. This indi-
cates that the wild-type allele is preferentially used by II.8 in CASK transcription.172 The American Journal of Human Genetics 84, 162–177, February 13, 2009
Conversely, we identiﬁed an aberrant out-of-frame CASK
transcript in which exon 2 is skipped, most probably as
a consequence of an altered recognition of ESE motifs by
SR proteins such as SF2/ASF or SRp55 (Figures 7 and 8). In
FGS4 lymphoblastoid cell lines, we detected exon 2 skip-
ping in approximately 3%–6% of total CASK transcripts
Figure 9. Relative Quantification of
CASK Expression
The analyzed cDNA samples are indicated
with respect to their position on pedigree
(Figure 2). CM and CF indicate control
male or female, respectively.
(A) The bar graph shows relative quantifi-
cation of the expression of different CASK
transcripts. The expression of the exon
2-skipped transcript (center), amplified
with CASKsp1-2/F and CASK268/R primer
pair, is significantly increased in I.2
(carrier female) as well as in II.17 and
III.26 (affected males). For II.8 (carrier
female), this aberrant transcript is unde-
tectable, even considering the wide interval
of error bar 5MSD). Expression levels
of CASK (right) detected with the
CASK2310/F and CASK2545/R primer pair
are reduced in the affected males (II.17
and III.26). The expression of the unskipped
CASK transcript (left), specifically amplified
with CASKsp1-3/F and CASK398/R primer
pair, is increased in carrier female II.8.
(B) Amplification plots describing the
kinetics of PCR reactions for different
targets and samples are presented. Differ-
ently colored curves correspond to GAPDH
(red), unskipped CASK transcript (blue),
CASK exon 2-skipped transcript (black),
and total CASK transcript (green). The
DCT obtained by subtracting the CT values
of the unskipped and exon 2-skipped
CASK forms is shown.
(C) After normalization, expression levels
of the unskipped CASK transcript were
compared to those of the exon 2-skipped
form. For each sample, the bar graph
shows the percentage accounting for the
CASK exon 2-skipped transcript ranging
between 3% and 6% in affected males
(II.17 and III.26) and carrier female
(I.2).
by quantitative RT-PCR (Figure 9).
Although we were unable to investi-
gate this effect in other patient tissues,
wespeculateadosage-dependentpath-
ogenetic effect related to the tempo-
rally and spatially speciﬁc expression
proﬁles of SR proteins during embryo-
genesis.
A large set of RNA-binding proteins, such as SR proteins,
show a regionally restricted expression proﬁle in devel-
oping mouse brain.58 ESE motifs are clustered and signiﬁ-
cantly enriched within exons compared with introns or
pseudo exons. In addition, differences in ESE motif
frequency distribution have been reported between exonsThe American Journal of Human Genetics 84, 162–177, February 13, 2009 173
with weak and strong splice sites for both 50 and 30 splice
sites.59 It is intriguing to observe that exons with weak 50
splice sites and exons with weak 30 splice sites were shown
to have more SRp55 and SF2/ASF motifs, respectively.59
The enrichment in SRp55-speciﬁc ESE consensus in the 50
half of CASK exon 2 resulting from the identiﬁed c.83G/
T transversion could weaken the 50 splice site of the exon,
possibly justifying the partially penetrant splice mutation
in our FGS patients. A silent p.D107D (c.321C/T) muta-
tion in the ATP6AP2 (MIM 300556) gene that similarly
produced an inefﬁcient inclusion of the exon 4 by altering
the recognition of an ESE motif was previously reported in
patients with XLMR and epilepsy.60
The selection between different splice sites is the result
of interactions involving the cooperative binding of
trans-acting splicing proteins to cis-acting sequence
elements in the pre-mRNA, and the regulation engages
multiple positively and negatively acting factors with
precise qualitative and quantitative ratios.61,62 Brain has
the highest proportion (>40%) of alternative spliced genes
that can inﬂuence neurophysiology through spatial and
temporal alterations in the expression of different classes
of proteins.61,63,64 Different types of neurological diseases
have been associated with defects in splicing.63
Altogether, our results suggest that the phenotype
observed in the FGS family under study should be consid-
ered a cis-acting splicing disorder interfering in the normal
CASK expression proﬁle during embryogenesis, brain
development, and differentiation.
A dosage-dependent CASK involvement in X-linked
mental retardation has previously been reported. By X
chromosome-speciﬁc CGH array, Froyen et al.65 indenti-
ﬁed a 15.5 Mb duplication in a male and a 3.2 Mb deletion
in a female, both involving CASK. Interestingly, the distal
break-point for the female was located within CASK, sug-
gesting that CASK haploinsufﬁciency might cause the
condition. Subsequently, another 4 Mb deletion encom-
passing CASK was also reported in a Japanese female,
showing marked mental retardation with microcephaly,
dysmorphic features, and cerebellar atrophy.66 By quanti-
tative RT-PCR analysis, CASK expression was shown to be
signiﬁcantly reduced in this patient compared with
controls.
More recently, a novel X-linked brain malformation
syndrome caused bymutations in CASK has been reported,
preferentially affecting females and characterized by se-
vere mental retardation, microcephaly, disproportionate
pontine, and cerebellar hypoplasia.67 Heterozygous loss-
of-function mutations of CASK were identiﬁed in four
females, whereas a partially penetrant splice mutation was
present in the only affected male presenting a more severe
phenotype, who died at 2weeks. Interestingly, the reported
p.K305K (c.915G/A) silent mutation in the affected male
gave rise to the skipping of the exon 9 in approximately
20% of transcripts in in vitro splicing assay.67
Unlike the affected females described by Najm et al.67 in
which de novo mutations inactivated one copy of CASK174 The American Journal of Human Genetics 84, 162–177, Februardetermining haploinsufﬁciency, females from this FGS
family carrying the p.R28L missense CASK mutation were
healthy with only very mitigated clinical signs in the
proband’s mother (II.8).12 In females carrying mutations
in X-linked genes, phenotypic variability can be modu-
lated by dosage compensation as observed in X-linked
disorders characterized by male lethality.68,69 Females are
mosaics of two cell populations with respect to X-linked
gene expression. The effect of the p.R28L mutant CASK
allele in the carrier females is most probably balanced by
the X chromosome inactivation. This is in agreement
with the observation that the two carrier females of the
FGS family under study differently utilized the wild-type
and mutant CASK allele for transcription (Figure 8C).
Our results and literature data suggest that mildly hypo-
morphic alleles could be a model for CASK mutations in
males, albeit representing very rare occurrences. CASK is
part of a complex and growing protein-protein network
with important functions in brain but also in other tissues.
Therefore, missense mutations altering CASK protein
functions should be expected in males, presumably associ-
ated with clinical variability, but with severe mental
retardation as a common trait.
Compared to the affected individuals described by Najm
et al.,67 our FGS patients shared only a few clinical signs
(Table S5).12 Severe mental retardation, a similar dysmor-
phic appearance, and a mildly abnormal EEG were present
in our surviving affected males. The main differences
included macrocephaly versus microcephaly and the
absence of evident anatomical abnormality in brain MRI,
with the exception of a persistent cavum septum/vergae.
The differences in the observed phenotypes are prob-
ably related to the complex and as yet incompletely
clariﬁed role of CASK in embryogenesis and CNS devel-
opment.
CASK must have a key role in regulating mammalian
development, given its high level of expression during
embryogenesis.23,56 The genetic defects that we and others
identiﬁed in CASK further highlight this point.65–67 In the
embryonic period, approximately 20% of CASK proteins
are present in the nuclei of neurons in cerebral cortex
and other brain regions.50 When associated with TBR1
and CINAP, CASK regulates the expression of different
genes such as RELN and NR2b, most likely playing an
important role in cerebral cortex development.51,52 Like-
wise, the growing protein-protein network established by
the cytoplasmic fraction of the multidomain CASK protein
seems to be important in synaptic interaction and forma-
tion, protein trafﬁcking, and synaptic targeting.47 All
these functions are most probably modulated by CASK
phosphorylation in a manner that needs to be further
elucidated.29,44
Supplemental Data
Supplemental Data include ﬁve tables and can be found with this
article online at http://www.ajhg.org/.y 13, 2009
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The URLs for data presented herein are as follows:
Allen Institute for Brain Science, Mouse Brain Atlas, http://www.
brain-map.org/
ClustalW software, http://www.ebi.ac.uk/Tools/clustalw2/index.
html
Entrez Nucleotide database at NCBI, http://www.ncbi.nlm.nih.
gov/sites/entrez?db ¼ nuccore
ESEﬁnder software, http://rulai.cshl.edu/cgi-bin/tools/ESE3/
eseﬁnder.cgi?process ¼ home
Eurexpress, a Transcriptome Atlas Database for Mouse Embryo,
http://www.eurexpress.org/
GeneDoc software, http://www.nrbsc.org/
GROMACS software version 3.2, http://www.gromacs.org/
MouseBrain Gene Expression Map (BGEM), http://www.
stjudebgem.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/sites/entrez?db ¼ omim
PDB Protein DataBank, http://www.pdb.org/pdb/home/home.do
Primer3, http://primer3.sourceforge.net
UCSC Genome Browser, http://genome.ucsc.edu/
Visual Molecular Dynamics (VMD) package, http://www.ks.uiuc.
edu/
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